| Followers | 1741 |
| Posts | 142045 |
| Boards Moderated | 4 |
| Alias Born | 09/11/2005 |
Saturday, August 29, 2015 6:26:11 PM
$PXYN-.0159???-RECORD-NET-PROFITS-2-MILLION-DOLLARS-PER-MONTH-SEC-FILED!!!-When-will-it-turn?
We are expecting Pharmacy Acquisition and NEW DIABETIC PRODUCT NEWS any day now.... This stock is amazing, in that it has reported MASSIVE REVENUES and NET PROFITS, but Wall Street doesn't know about it...
See for yourself...
Praxsyn's 2015 Anticipated Business Strategies
IRVINE, Calif., June 8, 2015 -- Praxsyn Corporation's (OTCQB:PXYN(link is external)) anticipated business plan for 2015 is to acquire a sister subsidiary retail community pharmacy and to purchase additional pharmacies. Mesa is also in the early stages of developing a program to supply medications and products to diabetic patients and anticipates the commencement of filling prescriptions by the end of the third quarter of 2015.
By expanding the number of pharmacies, Praxsyn believes they will be able to diversify and enlarge their range of products and their field of operations. The plans for a pharmacy acquisition, as well as the expansion into diabetic medications and products, fits with Praxsyn's business strategy of further diversifying their product lines as well as building and acquiring regional pharmacies.
"We are making key, target moves as we continue to grow our company, one of which is to be of service to patients who are suffering with diabetes," said Edward Kurtz, CEO of Praxsyn Corporation. "We plan to offer a variety of therapeutic products that meet the needs of diabetic patients."
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics(link is external). Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com(link is external).?
http://www.praxsyn.com/press_releases/praxsyns-2015-anticipated-business-strategies
$PXYN-Praxsyn-Pharma-Corp-Q2-2015-Earnings-Report-Summary
Gross Revenue - $27,600,000
Net Revenue - $17,600,000
Gross profit- $15,623,702
NET PROFITS before taxes - $5,500,000
NET PROFITS after taxes - $3,182,000
BASIC NET INCOME per SHARE - $0.01
Cash and cash equivalents, end of period - $4,839,476
Accounts receivable, net of current portion- $11,510,012
Total assets $26,004,489
Gross billings receivables sold $0.00 (no factoring)
Interest Expense
Interest expense for the second quarter of 2015 was $134,324 which predominantly resulted from interest on notes payable – no factoring was done in this period. For the comparable period of 2014, interest expense was $9,558,629 and consisted of factoring-related interest of $9,188,446 and other interest of $370,183.
https://www.sec.gov/Archives/edgar/data/1346973/000149315215003605/form10q.htm
We are expecting Pharmacy Acquisition and NEW DIABETIC PRODUCT NEWS any day now.... This stock is amazing, in that it has reported MASSIVE REVENUES and NET PROFITS, but Wall Street doesn't know about it...
See for yourself...
Praxsyn's 2015 Anticipated Business Strategies
IRVINE, Calif., June 8, 2015 -- Praxsyn Corporation's (OTCQB:PXYN(link is external)) anticipated business plan for 2015 is to acquire a sister subsidiary retail community pharmacy and to purchase additional pharmacies. Mesa is also in the early stages of developing a program to supply medications and products to diabetic patients and anticipates the commencement of filling prescriptions by the end of the third quarter of 2015.
By expanding the number of pharmacies, Praxsyn believes they will be able to diversify and enlarge their range of products and their field of operations. The plans for a pharmacy acquisition, as well as the expansion into diabetic medications and products, fits with Praxsyn's business strategy of further diversifying their product lines as well as building and acquiring regional pharmacies.
"We are making key, target moves as we continue to grow our company, one of which is to be of service to patients who are suffering with diabetes," said Edward Kurtz, CEO of Praxsyn Corporation. "We plan to offer a variety of therapeutic products that meet the needs of diabetic patients."
About Praxsyn Corporation
Headquartered in Irvine, California, Praxsyn works to realize the vision of medical professionals to improve the lives of patients. Mesa Pharmacy, a wholly owned subsidiary, provides doctors with an alternative to oral pain medications. Mesa focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and medical clinics(link is external). Mesa has developed a series of topical creams, in different strengths, that provide the pain relief doctors seek for their patients. Additional company information can be found at www.praxsyn.com(link is external).?
http://www.praxsyn.com/press_releases/praxsyns-2015-anticipated-business-strategies
$PXYN-Praxsyn-Pharma-Corp-Q2-2015-Earnings-Report-Summary
Gross Revenue - $27,600,000
Net Revenue - $17,600,000
Gross profit- $15,623,702
NET PROFITS before taxes - $5,500,000
NET PROFITS after taxes - $3,182,000
BASIC NET INCOME per SHARE - $0.01
Cash and cash equivalents, end of period - $4,839,476
Accounts receivable, net of current portion- $11,510,012
Total assets $26,004,489
Gross billings receivables sold $0.00 (no factoring)
Interest Expense
Interest expense for the second quarter of 2015 was $134,324 which predominantly resulted from interest on notes payable – no factoring was done in this period. For the comparable period of 2014, interest expense was $9,558,629 and consisted of factoring-related interest of $9,188,446 and other interest of $370,183.
https://www.sec.gov/Archives/edgar/data/1346973/000149315215003605/form10q.htm
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
